Do you think a class action lawsuit would be successful if
Do you think a class action lawsuit would be successful if they the 13d group on their first day in control sold Leronlimab for the value of the stock at whatever price they continue to purposely lower it to. Maybe by November they take the price below a dollar and then sell Leronlimab to IncellDX for a billion dollars which is over market value. 800,000,000 shares at a dollar isn’t quite a billion dollars so it’s sold above market value.
Their excuse is that they checked the balance of debt and thought they better sell before they went bankrupt. (Even though there is enough stock shares to make it until revenue.) saving the shareholder from a total loss. All they would have to say is we had just enough time to sell and settle our debts and not go bankrupt so we could save this drug before it was put back on the shelf.
What would be your answer then? Sold above stock value without us the stockholders realizing the true value of Leronlimab. Now the small group of investors who are invested in IncellDX’s private company complete the trials and get approvals a month or two after Cytodyn sold it to IncellDX. They see a huge return in approvals and we miss out.
Tell me how that is viewed by the courts in a class action lawsuit? Will they say we got the current value and that’s all that it was worth? Would they say that the future should be included in the value since trials were in progress? I think they would see us as unfortunate investors that got rooked by a smart investor group that stole our future investment before it could be realized and that is unfortunate for us but great deal for them… we lose in this situation.
Did you expect to have Leronlimab and Cytodyn sold out from under you for a dollar? Taken private by a small group of investors with a wealthy backer we don’t know of just yet.
Tell me how I am wrong and this isn’t possible? Tell me we need to trust a small investor group won’t do this? Tell me why they won’t do this? Tell me the courts won’t let them do it to us shareholders. Because I believe they can sell it their first day they take control and we lose our future potential and they steal all future potential. We get paid the actual value of the day they take over… how do we even file a class action lawsuit and for what do we file for? Loss of potential earning for a promise? Is this a real possibility?
Evil Rabbit I agree on 99% of your opinions and I see a smart group conspiring to make themselves rich at any cost. Tell me they care about us shareholders more than they care about themselves. Convince me they can’t sell the way I have stated it at current market value?
The one thing we know is that Nader and crew are genuine people that care about the shareholders and the people that are sick and in need of Leronlimab. We have seen who they are and what they stand for in all those situations. I know that I feel comfortable with our future with Nader and management one hell of a lot more than I do with this self enrichment group. There are many ways to skin a cat. But to be skinned by this 13d group will not feel good for any of us. Why should we trust them to not do something like I have suggested or slightly changed but still at market value before the value takes off.
10
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....
Continue Reading
AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...
Continue Reading
A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...
Continue Reading
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...
Continue Reading
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...
Continue Reading
When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...
Continue Reading
Top 5 Most Recently Viewed Articles
Exciting Development in Mental Health Treatment In a groundbreaking collaboration, BioXcel Therapeutics, Inc. (NASDAQ: BTAI) has joined forces with the University of North Carolina at Chapel Hill (UNC) thanks to a substantial grant from the U.S. Department of Defense. This grant aims to explore the effectiveness and safety of BXCL501, a novel treatment for acute stress...
Continue Reading
Alumni Champions of Environmental Research In a remarkable tale of collaboration fueled by a shared passion for wildlife research, Eastern Michigan University alumni Dorothy Zahor and Kenneth Glynn came together to explore environmental issues through the lens of urban wildlife. Their dedication to the study of American robins has revealed fascinating insights into how...
Continue Reading
Verkada Strengthens Global Channel Operations Verkada, known for its innovative cloud-based physical security solutions, recently announced a strategic enhancement in its global channel operations with the appointment of Micah Deriso as Head of Global Channel. This strategic move aims to bolster Verkada's global partnerships and streamline its channel strategy. Meet Micah...
Continue Reading
Purcell & Lefkowitz LLP Investigates Citi Trends, Inc. Recently, Purcell & Lefkowitz LLP announced an investigation concerning Citi Trends, Inc. (NASDAQ: CTRN). This inquiry arises from concerns regarding the fiduciary duties of the directors amidst ongoing corporate actions. The aim is to determine if there have been any breaches that may affect shareholders....
Continue Reading
Prairie Operating Co. Announces Successful Shelduck South Pad Completion Prairie Operating Co. (Nasdaq: PROP) has recently achieved a remarkable milestone with the timely completion of its Shelduck South pad in the DJ Basin. This accomplishment marks the successful culmination of the first phase of its development program for 2025, aiming for all production to be fully...
Continue Reading